STUDYING EGFR INTERACTING PARTNERS
STUDYING EGFR INTERACTING PARTNERS
批准号:
7722280
负责人:
HAROLD E. VARMUS
金额:
$0.33万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2009-02-28
关键词:
AntibodiesBindingBuffersCell Surface ReceptorsComputer Retrieval of Information on Scientific Projects DatabaseCytolysisEGFR Protein OverexpressionEpidermal Growth FactorEpidermal Growth Factor ReceptorExtracellular ProteinFamilyFiltrationFundingGRB2 geneGlioblastomaGrantHousingInstitutionLeadLigandsMalignant NeoplasmsMalignant neoplasm of lungMutationNumbersOryctolagus cuniculusPhosphorylation SiteProteinsResearchResearch PersonnelResourcesSepharoseSourceTestingTransforming Growth FactorsUnited States National Institutes of Healthgrowth factor receptor-bound protein 2magnetic beadsmembermutantreceptor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
EGFR (the epidermal growth factor receptor) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, being activated by binding to epidermal growth factor and transforming growth factor ¿ (TGF¿). Mutations that lead to EGFR overexpression have been associated with a number of cancers, including lung cancer and glioblastoma multiforme. To isolate EGFR with its interacting partners we tested several monoclonal and polyclonal commercially available anti-EGFR antibodies. However, none of these proved successful for immunoisolations. We therefore proceeded in testing in-house-developed antibodies (rabbit polyclonal), which we had to further purify to achieve antibodies usable for immunoisolations. After careful optimization of lysis buffers, and tests of magnetic beads versus agarose beads, we now have isolated EGFR with associated proteins. Our results confirmed previous known interacting partners, such as GRB2, and indicated numerous phosphorylation sites on EGFR. In our effort to obtain immunoisolations as clear as possible of background (non-specific binding), we tested the use of a filtration step prior to immunoisolations. Following filtration, we could still detect EGFR and GRB2. Having successfully isolated EGFR, we have now started the comparison between wild type and two mutant EGFR proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies of the initiation and progression of small cell lung cancer using cells derived by differentiation from human pluripotent stem cells
-
批准号:10358503
-
项目类别:
-
资助金额:$46.71万
-
财政年份:2018
-
负责人:HAROLD E. VARMUS
-
依托单位:
Studies of the initiation and progression of small cell lung cancer using cells derived by differentiation from human pluripotent stem cells
-
批准号:10089417
-
项目类别:
-
资助金额:$45.62万
-
财政年份:2018
-
负责人:HAROLD E. VARMUS
-
依托单位:
STUDYING EGFR INTERACTING PARTNERS
-
批准号:8361534
-
项目类别:
-
资助金额:$0.13万
-
财政年份:2011
-
负责人:HAROLD E. VARMUS
-
依托单位:
STUDYING EGFR INTERACTING PARTNERS
-
批准号:8169162
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2010
-
负责人:HAROLD E. VARMUS
-
依托单位:
Cancer Center Support Grant
-
批准号:7933199
-
项目类别:
-
资助金额:$362.59万
-
财政年份:2009
-
负责人:HAROLD E. VARMUS
-
依托单位:
Cancer Center Support Grant
-
批准号:7933196
-
项目类别:
-
资助金额:$47.88万
-
财政年份:2009
-
负责人:HAROLD E. VARMUS
-
依托单位:
STUDYING EGFR INTERACTING PARTNERS
-
批准号:7954131
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2009
-
负责人:HAROLD E. VARMUS
-
依托单位:
DEVELOPMENTAL FUNDS
-
批准号:7671785
-
项目类别:
-
资助金额:$93.27万
-
财政年份:2008
-
负责人:HAROLD E. VARMUS
-
依托单位:
Mouse Models for Tumor Progression and Maintenance
-
批准号:7438484
-
项目类别:
-
资助金额:$40.79万
-
财政年份:2008
-
负责人:HAROLD E. VARMUS
-
依托单位:
PLANNING and EVALUATION
-
批准号:7671783
-
项目类别:
-
资助金额:$5.25万
-
财政年份:2008
-
负责人:HAROLD E. VARMUS
-
依托单位:
Targeting EGFR and KRAS Mutations
-
批准号:7315933
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2007
-
负责人:HAROLD E. VARMUS
-
依托单位:
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice
-
批准号:7074974
-
项目类别:
-
资助金额:$42.22万
-
财政年份:2006
-
负责人:HAROLD E. VARMUS
-
依托单位:
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice
-
批准号:7474049
-
项目类别:
-
资助金额:$47.91万
-
财政年份:2006
-
负责人:HAROLD E. VARMUS
-
依托单位:
Mutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic Mice
-
批准号:7279274
-
项目类别:
-
资助金额:$46.25万
-
财政年份:2006
-
负责人:HAROLD E. VARMUS
-
依托单位:
Tumor maintenance and development in mouse models
-
批准号:6949695
-
项目类别:
-
资助金额:$42.15万
-
财政年份:2004
-
负责人:HAROLD E. VARMUS
-
依托单位:
Tumor maintenance and development in mouse models
-
批准号:7243485
-
项目类别:
-
资助金额:$45.87万
-
财政年份:2004
-
负责人:HAROLD E. VARMUS
-
依托单位:
Tumor maintenance and development in mouse models
-
批准号:6733967
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2004
-
负责人:HAROLD E. VARMUS
-
依托单位:
Tumor maintenance and development in mouse models
-
批准号:7105551
-
项目类别:
-
资助金额:$46.27万
-
财政年份:2004
-
负责人:HAROLD E. VARMUS
-
依托单位:
Tumor maintenance and development in mouse models
-
批准号:7392181
-
项目类别:
-
资助金额:$46.48万
-
财政年份:2004
-
负责人:HAROLD E. VARMUS
-
依托单位:
Cancer Center Support Grant
-
批准号:7347773
-
项目类别:
-
资助金额:$1387.95万
-
财政年份:1997
-
负责人:HAROLD E. VARMUS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: